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Introduction
Non-human primates, especially Old World monkeys, such as cynomolgus monkeys (Macaca fascicularis) and rhesus monkeys (Macaca mulatta) have been used to estimate the drug efficacy and toxicity due to their evolutionary closeness to humans. Common marmosets (Callithrix jacchus), belonging to New World monkeys, are attractive as small non-human primate models in drug metabolism studies due to genetic closeness, small body size, early sexual maturity, and high reproductive efficacy (Orsi et al., 2011; Sasaki, 2015) .
Human cytochrome P450 (P450) genes, encoding typical drug metabolizing enzymes, are composed of 57 functional genes and 58 pseudogenes. P450 enzymes, especially members of the 1, 2, and 3 families, play important roles in the metabolism of xenobiotics including various drugs, and some endogenous compounds. Human P450 1 enzymes include P450 1A1, 1A2, and 1B1. Human P450 1A1 mRNA is expressed in many tissues such as lung and trachea (Bieche et al., 2007) . In contrast, human P450 1A2 mRNA is predominantly expressed in liver. Human P450 1A and 1B enzymes are involved in 7-ethoxyresorufin O-deethylation, 7-ethoxycoumarin O-deethylation, benzo(α)pyrene hydroxylation, and estradiol hydroxylation (Shimada et al., 1997; Lee et al., 2003) . In marmosets, the only P450 1 enzyme identified to date is P450 1A2, which catalyzes metabolic activation of 2-amino-3-methyl-imidazo [4,5-f] quinolone and DMD # 67561 5 acid level. In particular, marmoset P450 3A, 2D, and 2C enzymes metabolize their respective typical human P450 probe substrates, but substrate selectivity of marmoset P450
2A enzyme partly differs from that of the human homologous enzyme. The molecular analysis of marmoset P450 enzymes is useful for understanding drug metabolism in marmosets; however, marmoset P450 1A and 1B enzymes have not been identified and fully characterized.
In this study, we found marmoset P450 1A1 and 1B1 genes by analysis of the marmoset genome sequence and report the results of cDNA analysis, tissue distribution at mRNA and protein levels, and enzymatic properties of marmoset P450 1A1, 1A2, and 1B1.
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Materials and Methods
Chemicals and enzymes
7-Ethoxyresorufin, resorufin, 7-ethoxycoumarin, 2-hydroxyestradiol, and 4-hydroxyestradiol were purchased from Sigma-Aldrich (Tokyo, Japan). Phenacetin, acetaminophen, 7-hydroxycoumarin, and β -estradiol were purchased from Wako Pure Chemicals (Osaka, Japan). Marmoset (pooled from 10 subjects), cynomolgus monkey (pooled from 10 subjects), and human liver microsomes (pooled from 150 subjects) were purchased from Corning Life Sciences (Woburn, MA). Brain, lung, liver, kidney, and small intestine tissue samples from eight marmosets (four males and four females, 2-6 years of age)
were obtained from the Central Institution for Experimental Animals (Kawasaki, Japan).
This study was approved by the Institutional Animal Care and Use Committee. Pooled marmoset tissue microsomes were prepared as described previously (Uehara et al., 2015d) .
Recombinant rat P450 1B1 was purchased from Nosan (Yokohama, Japan). Anti-human P450 1A1 (H-70), 1A2 (D-3), and 1B1 (H-105) antibodies, and anti-human PDI antibodies (H-160) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals used were the best grade available commercially.
P450 cDNA cloning
Total RNA was extracted from marmoset and cynomolgus monkey livers using RNeasy
Mini Kit (Qiagen, Valencia, CA), and the first-strand cDNA was synthesized using SuperScript III RT reverse transcriptase (Invitrogen, Carlsbad, CA) and oligo(dT) primers (Invitrogen). The cDNAs, encoding marmoset P450 1A1, 1A2, and 1B1, and cynomolgus monkey P450 1B1, were amplified from the first-strand cDNA templates by polymerase chain reaction (PCR) with KOD-Plus-Neo DNA polymerase (Toyobo, Osaka, Japan) in an 
mRNA quantification
Using the total RNA extracted from brain, lung, liver, kidney, and small intestine as described earlier, the first-strand cDNA was synthesized with random primers (Invitrogen) and SuperScript III RT reverse transcriptase (Invitrogen). Real-time PCR was performed with an ABI PRISM 7500 sequence detection system (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems). The primers used for real-time PCR
were: cjCYP1A1 (5qrt1) 5′-GCCCAATTCTTCCTTGAACAC-3′ and cjCYP1A1 (3qrt1) 5′-ATGTGCCCCTTCTCAAAGGTT-3′ for marmoset P450 1A1, cjCYP1A2 (5qrt1) DMD # 67561   8   5′-CACTATCAGGACTCTGACAAGAACAG-3′  and  cjCYP1A2  (3qrt1)   5′-CCCTGCTCCAAAGATGTCGT-3′ for marmoset P450 1A2, and cjCYP1B1 (5ex1a)   5′-TGGATTTGGCGGACGTACC-3′  and  cjCYP1B1  (3ex2a) 5′-ACATAGTGCAGGTTGGGCTG-3′ for marmoset P450 1B1. The real-time PCR conditions were as follows: 95°C for 10 min, followed by 40 cycles of 95 °C for 15 s and at 60°C for 1 min. All PCR reactions were carried out in triplicate, and the expression level of each P450 mRNA was normalized to the expression of 18S rRNA.
Immunoblotting
The protein expressions of P450 1A1, 1A2, and 1B1, and PDI in five marmoset tissues were verified by immunoblotting using anti-human P450 1A1, 1A2, and 1B1 antibodies, and anti-PDI antibodies, respectively. Pooled tissue microsomes (40 μ g) or recombinant P450
proteins (1 pmol equivalent) were loaded on a 10% sodium dodecyl sulfate-polyacrylamide gel, separated by electrophoresis, and transferred to a polyvinylidene difluoride membrane (Merck Millipore, Billerica, MA). The membranes were blocked with Tris-buffered saline containing 0.05% Tween 20 and 0.5% nonfat dry milk for 30 minutes at room temperature, and were incubated with anti-human P450 1A1 (1:5000), anti-human P450 1A2 antibodies
(1:5000), or anti-human P450 1B1 antibodies (1:1000) at room temperature for 1 hour.
Then, the membranes were washed for 10 minutes three times, and were incubated with anti-rabbit and mouse IgG secondary antibody (Santa Cruz Biotechnology, 1:5000) at room temperature for 20 minutes. Protein bands were detected using ECL Prime Western Blotting Detection System (GE Healthcare, Buckinghamshire, UK) according to the manufacturer's instructions.
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Heterologous protein expression in Escherichia coli
Recombinant marmoset P450 1A1, 1A2, and 1B1, and cynomolgus monkey P450 1B1
were prepared in Escherichia coli using pCW vector (co-expressed with NAPDH-P450 reductase) as described previously (Uehara et al., 2015d) . The cDNAs were modified N terminus by PCR amplification using primers containing the restriction sites of the NdeI and XbaI sites (underlined). PCR primers were cjCYP1A1 (5exp1bov) 5′-GGAATTCCATATGGCTCTGTTATTAGCAGTTTTTGTCACGGAGCTTCTCCTGGCCTC T-3′ and cjCYP1A1 (3exp1) 5′-GCTCTAGACTAAGAGCGCAGCTGCATTTGGAA-3′ for
5′-GGAATTCCATATGGCTCTGTTATTAGCAGTTTTTTTCTCAGCCACAGAGCTTCTC CT-3′ and cjCYP1A2 (3exp1) 5′-GCTCTAGACGGTGTCTTCCTCACTGGAAGG-3′ for marmoset P450 1A2, cjCYP1B1 (5exp1bov) 5′-CATATGGCTCTGTTATTAGCAGTTTTTGACCCTTGGCCGCTAAAC-3′ and cjCYP1B1
(3exp1) 5′-TCTAGATTATTGGCAAATTTCCTCGGCTTG-3′ for marmoset P450 1B1, and mfCYP1B1 (5exp1bov) 5′-CATATGGCTCTGTTATTAGCAGTTTTTGACCCTTGGCCTCTAAAC-3′ and mfCYP1B1
(3exp1) 5′-TCTAGATTATTGGCAAGTTTCCTCAG-3′ for cynomolgus monkey P450 1B1.
For marmoset P450 1A1 and 1A2, PCR products were cloned into pCW vectors after restriction enzyme reaction. For marmoset and cynomolgus monkey P450 1B1, PCR products were first cloned into pGEM-T easy vectors, and then subcloned into pCW vectors after restriction enzyme reaction. Insert sequences were verified by DNA sequencing as described earlier. Expression plasmids of human P450 1A1, 1A2, and 1B1, and cynomolgus monkey P450 1A1 and 1A2 proteins with NADPH-P450 reductase were prepared as described previously (Yamazaki et al., 2002; Uno et al., 2011) . Expression of these P450 proteins was carried out as described previously (Yamazaki et al., 2002; Uno et al., 2011) .
The membrane fractions from E. coli DH5α expressing P450 proteins were prepared by sonication and centrifugation, and the concentrations of P450 protein and NADPH-P450 reductase were measured as described previously (Yamazaki et al., 2002) .
Enzymatic characterization and kinetic analysis
7-Ethoxyresorufin O-deethylation, 7-ethoxycoumarin O-deethylation, and phenacetin
O-deethylation activity of recombinant proteins and liver microsomes were determined for enzymatic characterization as described previously (Uehara et al., 2015c; Uehara et al., 2015d) . For the kinetic analysis for 7-ethoxyresorufin O-deethylation, the incubation mixture containing 1.0 pmol equivalent of recombinant P450 protein or 0.04 mg liver microsomes, an NADPH-generating system (0.25 mM NADP+, 2.5 mM glucose 6-phosphate, and 0.25 units/mL glucose 6-phosphate dehydrogenase), and 0.05-10 μM 7-ethoxyresorufin in 100 mM potassium phosphate buffer (pH7.4) in a final volume of 0.25 mL were incubated at 37°C for 10 minutes. For estradiol 2-and 4-hydroxylation, the incubation mixture contained 10 pmol equivalent of recombinant P450 protein or 0.5 mg liver microsomes, an NADPH-generating system, and 100 μM estradiol in 100 mM potassium phosphate buffer (pH7.4) in a final volume of 0.25 mL. After a 3-minute pre-incubation at 37°C, the reaction was initiated by adding NADPH and incubated at 37°C for 30 minutes. Linearity for metabolite formations with incubation time and protein concentrations were confirmed under these conditions. After the reactions were terminated with ethyl acetate and centrifuged at 2500 g for 5 minutes. The supernatants were evaporated in a rotary evaporator under vacuum and the dry residues were dissolved in the HPLC mobile phase. The samples were subjected to HPLC in an analytical C18 column (Mightysil, 5 μ m, 150×4.6 mm; Kanto Chemical) with elution by a 33% acetonitrile/0.1% acetic acid, and the metabolites were 
Sequence analysis
The homology of amino acid sequences was analyzed using BLAST (National Center for Biotechnology Information). The multiple sequence alignment was performed with
Genetyx system (Software Development, Tokyo, Japan). The phylogenetic analysis was conducted by the neighbor-joining method using DNASIS Pro (Hitachi Software, Tokyo, Japan). P450 amino acid sequences used were obtained from GenBank; marmoset P450
1A2 ( To identify the P450 1A1 and 1B1 in marmosets, we first searched against the marmoset genome database using the human P450 1A1 and 1B1 cDNA sequences, resulting in the discovery of unpublished marmoset P450 1A1 and 1B1 gene sequences. We cloned the coding sequence of marmoset P450 1A1 (1536 bp) and 1B1 (1629 bp) cDNAs from the marmoset liver by reverse transcription-PCR with gene-specific primers. Analysis of the deduced amino acids of P450 1A1 (512 residues) and 1B1 (543 residues) showed that the primary structure of these P450s had well-conserved sequence regions including six substrate recognition sites (SRSs) and the heme-binding region (Figs. 1 and 2). The amino acid sequences of marmoset P450 1A1 and 1B1 possessed 90% and 92-93% identities with the homologous human, and cynomolgus and rhesus monkey P450 enzymes, and the sequence identities were higher than those of other species (Tables 1 and 2 ). Marmoset P450 1A2
cDNA previously reported was also isolated to compare the enzymatic function with marmoset P450 1A1 and 1B1 in this study. A phylogenetic comparison of P450 1A and 1B enzymes of various animal species (Fig. 3 ) demonstrated that marmoset P450 1A and 1B enzymes, respectively, had evolutionary closeness with human P450 1A and 1B enzymes, similar to cynomolgus monkey and rhesus monkey P450 1A and 1B enzymes, but unlike dog, rabbit, rat, or mouse P450 1A and 1B enzymes.
Tissue expression pattern of marmoset P450 1A1, 1A2, and 1B1 mRNA
To determine the distribution of P450 1A1, 1A2, and 1B1 mRNA in marmoset tissues, real-time PCR was carried out in brain, kidney, liver, lung, and small intestine (Fig. 4 ).
Marmoset P450 1A1 mRNA was mainly expressed in small intestine, lung, and brain.
This article has not been copyedited and formatted. The final version may differ from this version. Marmoset 1B1 mRNA was expressed in most of the extrahepatic tissues (kidney > lung > brain > small intestine > liver). Marmoset P450 1A2 mRNA expression was most abundant in liver. Next, P450 1A1, 1A2, and 1B1 protein expressions were detected in five marmoset tissues by immunoblotting using anti-human P450 1A1, 1A2, and 1B1 antibodies.
Recombinant marmoset P450 1A1, 1A2, and 1B1 were selectively detected with anti-human P450 1A1, 1A2, and 1B1 antibodies, respectively (Fig. 5A ). Marmoset P450 1A1 protein was expressed in lung and small intestine, and at much lower levels in liver and kidney (Fig.   5B ). Marmoset P450 1B1 protein was extensively expressed in lung, liver, kidney, and small intestine, and at a much lower level in brain (Fig. 5B ). An approximately 54-kDa band was detected in liver microsomes by immunoblotting using anti-human P450 1A2
antibodies ( Fig. 5B ), indicating that marmoset P450 1A2 protein was predominantly expressed in liver. These results suggest a predominant expression of marmoset P450 1A2
protein in liver and more abundant expression of marmoset P450 1A1 and 1B1 proteins in the extrahepatic tissues.
Enzymatic properties of marmoset P450 1A1, 1A2, and 1B1
To determine the catalytic properties of marmoset P450 1A1, 1A2, and 1B1, metabolic activities were measured using the typical human P450 1A and 1B substrates, 7-ethoxyresorufin, 7-ethoxycoumarin, and phenacetin for recombinant P450 1A1, 1A2, and 1B1 proteins, and marmoset, cynomolgus monkey, and human liver microsomes. Marmoset P450 1A1, 1A2, and 1B1 enzymes, and marmoset liver microsomes catalyzed
7-ethoxyresorufin O-deethylation, 7-ethoxycoumarin O-deethylation, and phenacetin
O-deethylation, similar to those of humans and cynomolgus monkeys (Tables 1 and 2 Similarly, marmoset P450 1A1 and 1A2 enzymes more efficiently catalyzed 7-ethoxyresorufin O-deethylation compared with those of humans and cynomolgus monkeys.
These findings indicated that marmoset P450 1A and 1B enzymes catalyzed typical human P450 probes.
A previous study showed that the estradiol hydroxylation specificity of P450 1B1
enzyme differed between those of humans and rats (Nishida et al., 2013) . To determine the estradiol hydroxylation specificity of marmoset P450 1B1, estradiol 2-and 4-hydroxylation activities were compared with rat, cynomolgus monkey, and human P450 1B1. Marmoset P450 1B1 preferentially catalyzed estradiol 4-hydroxylation, similar to those of humans and cynomolgus monkeys, but rat P450 1B1 more favorably catalyzed estradiol 2-hydroxylation.
Therefore, estradiol hydroxylation specificity of marmoset P450 1B1 enzyme was similar to those of human and cynomolgus monkey P450 1B1.
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Discussion
Common marmosets have been used in the preclinical studies for drug development due to various advantages as an experimental animal. However, P450s, major drug metabolizing enzymes, have not been fully identified and analyzed in marmosets. In our previous study, the tissue-specific expression patterns of P450 1-3 like genes were shown (Shimizu et al., 2014) . In this study, we newly cloned P450 1A1 and 1B1 cDNAs from marmoset livers by RT-PCR using the gene-specific primers designed based on the marmoset genome sequences.
Marmoset P450 1A1, 1A2, and 1B1 had high sequence identities (>88%) to the homologous human P450 at amino acid level. Physiologic analysis also indicated the evolutionary closeness of marmoset P450 1A and 1B to those of humans, cynomolgus monkeys, and rhesus monkeys (Fig. 3) . 1A2 has a high K m in both. These results suggest that marmoset P450 1A enzymes have enzyme characteristics similar to human and cynomolgus monkey P450 1As with some functional differences between primate species, in spite of their high sequence identities.
Therefore, further functional studies of P450 1A and 1B enzymes between primate species would be interesting.
Marmoset P450 1A1 mRNA and protein were mainly expressed in lung and small intestine among the five tissues analyzed (Figs. 4 and 5 ). In humans, P450 1A1 mRNA is mainly expressed in the extrahepatic tissues such as lung, trachea, and small intestine (Bieche et al., 2007) . Marmoset P450 1B1 mRNA was mainly expressed in most of the extrahepatic tissues analyzed, including kidney and lung, and at a much lower level in liver. Similarly, P450 1B1 protein was also expressed in all these five tissues (Fig. 5) . In humans, P450 1B1 mRNA is expressed in the extrahepatic tissues, particularly in prostate, uterus, trachea, lung, and kidney (Bieche et al., 2007) . A previous report showed an abundant expression of marmoset P450 1A2 mRNA in liver (Sakuma et al., 1997) , similar to human P450 1A2 mRNA (Bieche et al., 2007) . P450 1A2 is expressed much more abundantly than P450 1A1 in marmoset liver (Sakuma et al., 1997) , similar to that of humans (Shimada et al., 1994) . In contrast, cynomolgus monkey P450 1A1 mRNA is expressed in liver much more abundantly than P450 1A2 mRNA (Sakuma et al., 1998) , indicating that marmosets and humans might share the mechanisms of the P450 1A basal transcriptional regulation in liver, unlike cynomolgus monkeys. These findings indicated that tissue distribution of marmoset P450
1A and 1B was similar to those of human P450 1A and 1B.
This article has not been copyedited and formatted. The final version may differ from this version. The P450 1A gene family is transcriptionally induced by a polycyclic aromatic hydrocarbon such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 3-methylcholanthren through aryl hydrocarbon receptor (Nebert and Dalton, 2006) . P450 1A1, expressed in human liver at quite a low level, is inducible upon exposure to TCDD (Drahushuk et al., 1998) . Marmoset P450 1A1-and 1A2-like protein expressions in liver are greatly induced by TCDD-, but not by phenobarbitone, rifampicin, or clofibric acid (Schulz et al., 2001 ). In human and cynomolgus monkey livers, P450 1A1 is greatly induced by TCDD, but P450
1A2 shows only modest induction (Edwards et al., 1994; Drahushuk et al., 1996) .
Additionally, P450 1A2 mRNA is induced by 3-methylcholanthrene in marmosets, cynomolgus monkeys, and humans (Sakuma et al., 1997; Sakuma et al., 1998; Rhodes et al., 2011) . These findings suggest that P450 1A genes might share the mechanisms of the transcriptional activation in marmosets, cynomolgus monkeys, and humans.
Human P450 1A1, 1A2, and 1B1 enzymes predominantly catalyze estradiol 2-and 4-hydroxylation, but with different metabolite ratios (Lee et al., 2003) . Marmoset P450 1A1
and 1A2 enzymes predominantly catalyzed estradiol 2-hydroxylation similar to those of humans and cynomolgus monkeys (Table 5) . Additionally, P450 1A2 enzymes had higher estradiol 2-hydroxylation activity than P450 1A1 enzymes in marmosets, cynomolgus monkeys, and humans. In contrast, P450 1B1 enzymes of marmosets, cynomolgus monkeys, and humans predominantly catalyzed estradiol 4-hydroxylation, unlike that of rats (Table 5 ).
V395 in human P450 1B1 could account for the differential estradiol hydroxylation specificities (Nishida et al., 2013) . V395 in marmoset P450 1B1 might contribute to specific estradiol 4-hydroxylation similar to that of human P450 1B1. These findings indicated that the estradiol hydroxylation specificity of P450 1A1, 1A2, and 1B1 is similar among marmosets, cynomolgus monkeys, and humans.
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